Skip to main content
SpringerLink
Log in

Gastric cancer

Zolbetuximab treatment in metastatic gastric cancer

  • In Brief
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

  • Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(23)00620-7 (2023)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Gastroenterology & Hepatology http://www.nature.com/nrgastro/

    Eleni Kotsiliti

Authors
  1. Eleni Kotsiliti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eleni Kotsiliti.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kotsiliti, E. Zolbetuximab treatment in metastatic gastric cancer. Nat Rev Gastroenterol Hepatol 20, 344 (2023). https://doi.org/10.1038/s41575-023-00785-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00785-0

  • Springer Nature Limited

Search

Navigation